| Autor: |
R. Hernández San Gil, E.M. Rodríguez Rodríguez, L.M. Rodríguez Rodríguez, H. Roldán Delgado, J. Cruz Jurado, M.J. Sánchez Pérez, M.J. de la Vega Prieto, L.S. Medina Vega, M.A. Gómez Rodríguez-Bethencourt, J. Oramas Rodríguez, B.E. Alonso Álvarez, J.N. Batista López |
| Jazyk: |
English<br />Spanish; Castilian |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Medicina Clínica Práctica, Vol 4, Iss 1, Pp 100156- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2603-9249 |
| DOI: |
10.1016/j.mcpsp.2020.100156 |
| Popis: |
Women with breast cancer who receive aromatase inhibitors (AI) are at risk of bone mass loss and bone fracture. Many of these women have been previously treated with chemotherapy and/or tamoxifen, also with known deleterious bone effects. We studied the bone mineral status of a group of postmenopausal women with non-advanced breast cancer about to initiate AI treatment.Between 2007 and 2010, 127 women aged 63 ± 9 years were prospectively included. Clinical, epidemiological, analytical, radiological, and densitometric data were collected.Prior to initiating AI treatment, the patients exhibited a high prevalence of bone mass loss (62.2%): 16.5% had osteoporosis and 45.7% osteopenia by OMS criteria. Besides, 7.4% of their dorso-lumbar spine x-rays revealed one or more vertebral fractures, all of which were found in patients with densitometry-defined osteoporosis or osteopenia. Surprisingly, 25-OH-vitamin D levels were normal (≥30 ng/ml) in 87.4% of the women. Obesity was prevalent (BMI 30 ± 5). Their most common tumour was infiltrating ductal carcinoma (76.4%). The women who had received adjuvant chemotherapy (50%) were younger (59.1 ± 8.3 vs. 66.2 ± 8.2, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
